Patent Application
20180312829
This application is based upon and claims priority to Chinese Patent Application No. 201710282955.4 (CN), filed on Apr. 26, 2017, the entire contents of which are incorporated herein by reference.
The present invention relates to the field of biotechnology, specifically relating to a directionally modified glucosamine synthase mutant and its application.
Glucosamine, GlcN in short, the main component of proteoglycans and glycoproteins, exists in various organisms and can be translated into glucose-6-phosphate inside the cell through amination. N-acetyl-d-glucosamine (GlcNAc) is widely used in medicine, food, daily chemical and other fields. Traditionally, the GlcNAc is produced by acid hydrolysis, using the chitin of shrimps and crabs as raw material. The reaction requires concentrated acid and high temperature conditions, which will cause serious environmental pollution, and the equipment requirement is strict and the production cost is high. With the rapid development of metabolic engineering and synthetic biology, biological fermentation method used in the industrial yield is becoming more and more mature. The glucose is used as a raw material to directly convert into glucosamine, which has the advantages of low material cost, simple extraction, high purity of the product, less pollution and so on.
Glucosamine synthase (GLS) is the key enzyme of GlcN biosynthesis, which can catalyze fructose-6-phosphate to generate GlcN-6-P with the glutamine as amino donor. This is the first rate-limiting reaction in the synthesis pathway of GlcN, and GLS is seriously affected by the product inhibition effect of the metabolite GlcN-6-P. Therefore, GlcN-6-P cannot be largely accumulated in the normal metabolic synthesis. In order to reduce the inhibition of the product, co-expression of glucosamine acetyltransferase gene is usually used in the E. coli system to convert the GlcN-6-P in the metabolic system into GlcNAc-6-P with a small stimulation Both the product GlcN-6-P and GlcNAc-6-P can be transferred from intracellular to extracellular, and be dephosphorylated into GlcNa and GlcNAc respectively, while GlcNAc can be converted into GlcN through deacetylation under the acidic condition. The low biosynthetic ability and poor tolerance to the product of GLS are the main reasons that limit the increase in the yield. Although strains used in current industrial yield have far exceeded the level, most of which were optimized through metabolic engineering and fermentation control, but the literature analysis shows that one focus of the transformation is glucosamine synthase.
The present invention is intended to provide a method for constructing engineering bacteria with high yield of glucosamine through cloning and expressing of glucosamine synthase via gene engineering and modification of glucosamine synthase via error-prone PCR. This method is a simple and effective technique for obtaining DNA sequence variation of specific genes, which has great application prospect in genetic research and genetic improvement studies. The method has the advantages of short cycle, low energy consumption and less pollution, and it's suitable for the requirements of industrial yield.
To provide a new transformation strategy to modify the GLS, better expression plasmid and expression hosts are firstly screened, and then the error-prone PCR is used to irrationally modify the GLS. Glucosamine is added into the medium as screening pressure to screen the mutant strains with enhanced tolerance. In addition, the invention also attenuates the inhibitory effect of GlcN accumulation to the host cell through co-expressing the glucosamine acetyltransferase GNAL, and to investigate the synthesis ability of mutation strains.
A directionally modified glucosamine synthase mutant, consisting of the amino acid sequence shown in sequence list SEQ ID No. 1.
The gene of the directionally modified glucosamine synthase mutant, consisting of the nucleotide sequence shown in sequence list SEQ ID No. 2.
A genetic engineering bacteria carrying a gene of the directionally modified glucosamine synthase mutant are included.
An application of the directionally modified glucosamine synthase mutant in the biosynthesis of glucosamine, through a co-expression of glucosamine acetyltransferase, glucosamine of the fermentation system is converted into acetylated glucosamine to reduce the product inhibitory effect and improve yield of glucosamine.
A method for directional modifying glucosamine synthase via genetic engineering method comprises cloning and expressing the glucosamine synthase gene, establishing a mutant library using the continuous error-prone PCR for high-throughput screening to obtain glucosamine synthase mutant M15-9 with improved fermentation performance.
The amino acid sequence of the modified glucosamine synthase comparing with the wild-type, the Ala residue at position 60 is changed into Ser, Val at position 128 is changed into Ala, Asp at position 352 is changed into Ala, Arg at position 354 is changed into Cys, lie at position 422 is changed into Met, Leu at position 423 is changed into Val, Asp at position 471 is changed into Glu, Leu at position 567 is changed into Glu. The mutation is a cumulative result of several rounds. Structure analysis showed that the hydrophobicity of the mutant enzyme increased significantly compared to the wild-type, resulting in the gathering of the residues in the active center inwards or sideways. At the same time, the hydrogen bond of the mutant enzyme is strengthened. Besides, the negatively charged amino acids are significantly reduced and converted into neutral amino acids, which weakens the polarity of the enzyme and benefits the combination of enzyme and substrate. The above changes change the spatial conformation of the enzyme, increase the combination region of enzyme and substrate, and improve the combination efficiency of enzyme and substrate.
Compared to prior art, the present invention has the following benefits: The present invention clones and expresses glucosamine synthase through gene engineering. The best expression system is optimized through the screening of different expression plasmids and hosts. Given E. coli as an example, the engineering bacteria of E. coli Rosetta-gami (DE3)-pET-24a-gls is successfully constructed and obtained, and its detected glucosamine yield of glucosamine is 1.63 g/L. In order to improve the tolerance of the recombinant bacteria against glucosamine, the glucosamine is directionally modified by error-prone PCR technology. A high productive GIcN bacterial strain is screened from about 2700 mutant strains via high throughput screening method. The GIcN yield reaches 3.57 g/L, which is 1.19 times as compared to that of starting strain. As the accumulation of GIcN inhibits the growth and metabolism of the glucosamine synthase recombinant bacteria, it is further converted into acetylated glucosamine GlcNAc through co-expression of glucosamine acetyltransferase GNAL in the present invention to reduce the inhibitory effect of the product. The result shows that the tandem expression of GNAL and GLS can significantly improve the fermentation ability of the bacteria strains, and the cumulative yield of GIcN and GIcNAc reaches 7.83 g/L, which is 2.19 times as compared to that of the single expression of GLS. After a test of the preliminary flask fermentation optimization and 5 L tank fermentation, the results show that the glucosamine fermentation level is basically stable, the highest yield after 22 hours' fermentation reaches 9.85 g/L.
In the figure, M: Marker: lane 1 and lane 2: gls gene obtained from PCR, the target band can be seen in about 1800 bp.
In the figure, •: pET-28a, ▪: pET-24a, ▴: pRSFDuet-1, ♦: pET-22b, A: the expression host of E. coli BL21(DE3); B: E. coli BL21(DE3) piss; C: E. coli Rosetta-gami(DE3).
In the figure, •: Original strain; ▪: The first round of optimal mutant; ▴: The second round of optimal mutant; ♦: The third round of optimal mutant.
In the figure, (A) is wild-type enzyme, (B) is mutant enzyme M15-9.
In the figure, (A) is wild-type enzyme, (B) is mutant enzyme.
In the figure, (A) is wild-type enzyme, (B) is mutant enzyme.
In the figure, 1 referred to recombinant bacteria with no gls mutation; 2 referred to recombinant bacteria with a gls mutation; 3 referred to recombinant bacteria co-expresses both gls and gnal after the mutation.
In the figure: •: GlcNAc, ▴: GlcN, ▪: GlcNAc+GlcNAc, ♦: OD600, ⋄: pH.
The embodiments of the present invention are described in detail below. The scope of the present invention is not limited by the specific embodiments.
Design primers according to the gls gene, the primer in 5′ terminal is gls (1), the primer in 3′ terminal is gls (2). Design primers according to the gnal gene the primer in 5′ terminal is goal (1), the primer in 3′ terminal is gnal (2). The primer sequences related in the present invention are shown in table 1.
CCGGAATTCTTATTCAACGGT
CCCAAGCTTAAGGAGATATA
CCGCTCGAGTTATTTACGAAT
The gls gene is cloned by primers gls (1) and gls (2). Extaq polymerase is used to amplify in the reaction. The reactions are carried out in a 50 μL reaction system with the following PCR conditions: pre-denaturation at 94° C. for 10 min; denaturation at 94° C. for 30 s, annealing at 62° C. for 45 s, extending at 72° C. for 60 s, 35 cycles; final extending at 72° C. for 10 min. The PCR product is electrophoresed on 1.0% agarose gel (
Four different expression plasmid, pET-22b, pET-24a, pET-28a and pRSFduet-1 are selected respectively. The expression plasmids are conducted enzyme digestion by EcoR I and BamH I. Gls is connected to the expression plasmids through the T4 ligase to construct the recombinant plasmids pET-22b-gls, pET-24a-gls, pET-28a-gls and pRSFduet-1-gls respectively. E. coli Rosetta-gami (DE3), E. coli BL21 (DE3), E. coli BL21 (DE3) piss are taken as expression host to establish different gls recombinant expression systems. IPTG is added into the positive clone after screening to conduct induced expression. The result shows that when pET-24a is taken as expression plasmid, the expression system obtained the highest glucosamine synthesis ability, which reaches at 1.31 g/L, 1.37 gL and 1.63 g/L in E. coli BL21 (DE3), E. coli BL21 (DE3) piss and E. coli Rosetta-gami (DE3) respectively (See
In order to improve the tolerance of glucosamine synthase against glucosamine and the yield ability of glucosamine, the glucosamine synthase is conducted to directional modify the GLS via error-prone PCR. The reaction system of error-prone PCR after optimization is as shown in table 2:
The PCR reaction condition: starts with pre-denaturation at 94° C. for 10 min; followed by 30 cycles of denaturation at 94° C. for 30 s, annealing at 62° C. for 45 s, extending at 72° C. for 60 s; with a final extending at 72° C. for 10 min. After PCR reaction, PCR products are conducted 1.0% agarose gel electrophoresis. The target bands are excised from the gel and eluted using Elution buffer to conduct re-dissolution. The PCR product is conducted 1.0% agarose gel electrophoresis to gel extract the target sequences through the gel extraction kit. The gls and pET-24a are conducted double enzyme digestion by BamH I and EcoR I, then pET-24a-gls recombinant plasmid is constructed through T4 ligase reaction.
The mutant recombinant plasmid is converted into E. coli Rosetta-gami (DE3), transferring to be conducted domestication in 5 mL LB medium contained 25 g/L of glucosamine, culturing under the condition of 37° C., 220 rpm for 10 h. The cultured bacterial fluid is coated on the solid plate containing 25 g/L of glucosamine and cultured in the 37° C. incubator for 12 h, the growth situation of the bacterial colony is real-time monitored. The transformant is selected and transferred into the TB liquid medium containing 3% of glucose to culture in the 96-deep well cultural plate, at the same time, each of the selected bacterial strain is made superscript in the well cultural plate. Each well correspond to a positive transformant, while two wells are reserved as contrast, one added with the starting strain, the other added with the culture medium only but no any strains. The culture condition is 37′C, 220 rpm. When the OD600 is 0.6-0.8 in culture, the IPTG with a final concentration of 0.5 mM is added into and conducted induction of enzyme yield, and the culture condition changes into 25° C., 220 rpm. The glucosamine content is determined after fermentation for 24 h.
After the fermentation, the deep well plate is taken out to conducted centrifugation, and then 100 μL acetylacetone reagent is added into the deep well plate. And then the deep well plate is fixed in a water bath at 90° C. to conduct water bath for 1 h. After removed out from the water bath and cooled down, 1 mL of 96% ethanol is added to the deep well plate, and then 100 μL DMAB reagent is added. Then coloring at room temperature for 1 h, after that, 200 μL of the sample is corresponding sucked from the deep well plate to the 96-deep well plate by a volley. The 96-well plate is placed on a microplate reader to measure the spectrophotometric values at 530 nm to screen out the strains whose OD530 are higher than that of the starting strain. The screened strains are selected from the plate to culture and measure the yield of GIcN.
The pET-24a-gls is taken as a template in the experiment. When gls is mutated in vitro via error-prone PCR technology, the high concentration GIcN is applied to conducted domestication to select the mutant strains through high throughput screening on the 96-well plate. 22 mutant strains with improved yield traits are screened from 1152 cloned strains in the first round of error-prone PCR. After screening verification, the yield of the mutant strain numbered M4-27 is 2.84 g/L, increased by 74.2%. Plasmids of the mutant strain are extracted as a template to conduct the next round of mutation and screening, 15 mutant strains are selected from 864 cloned strains. The highest yield is 3.39 g/L (Number M6-9). 20 mutant strains are selected from 691 cloned strains in the third round experiment, the highest yield reaches 3.57 g/L (Number M15-9), the yield of which cumulatively increased by 119% (See
The original strain MO-0 and the best mutant strain M15-9 are inoculated in the LB seed culture medium, and transferred to ferment in the TB (3% glucose) fermentation medium under the condition of 37° C., 220 r/min. When OD600 of bacterial fluid reaches 0.6-0.8, the IPTG is added into the fermentation broth and conducted induction at 25° C., the final concentration of IPTG is 0.5 mmol/L. The yield is determined after fermentation is conducted for 18 hs' later. The comparison of each indexes of wild bacteria and mutant bacteria is as shown in table 3.
By controlling the content of MnCl2 and dGTP in the reaction system in the embodiment, the base mutation rate is controlled within 2-3% to ensure the positive mutations can be obtained in each round of mutant strains. The mutational bases and amino acid sites of each round are shown in Table 4. The strain M15-9 with high and stable yield is obtained through multi-round advantage accumulation. The nucleotide sequence of the mature protein of the mutant enzyme is as shown in SEQ ID NO.2 and the amino acid sequence of which is as shown in SEQ ID NO. 1. The amino acid sequence of the wild-type glucosamine synthase is as shown in SEQ ID NO.3 and the amino acid sequence of which is shown as SEQ ID NO.4.
Construction of glucosamine synthase model: The online software SWISS-MODEL is used to conduct homology modeling to obtain the three-dimensional structure model of glucosamine synthase via protein sequences analysis with high internal homology from the protein database (PDB). Through sequence and structure analysis show that there are two sites changed near the active center 5 Å of the three-dimensional structure in glucosamine synthase. The changes of mutation sites 352 (D-A) and 354 (R-C) have a significant influence to the combination region of the substrate fructose-6-phosphate. Specific changes are as follows:
{circle around (1)} Comparison of Hydrophobic
As
{circle around (2)} Comparison of Hydrogen Bonds
As shown in
{circle around (3)} Comparison of the Charge
The change in amino acid residues of the enzyme leads to the significant reduction of the negatively charged amino acids of the mutant enzyme compared to wild type as shown in
Because of its less stimulation to cells and ability to conduct deacetylation to convert into GlcN by weak acid in the downstream extraction process, the acetylglucosamine is often chosen as the fermentation product. The gnal gene is amplified by primer gnal (1) and gnal (2). The PCR product is conducted 1.0% agarose gel electrophoresis to gel extract the target sequences, then the gls and pET-24a-gls are conducted double enzyme digestion by Hind III and Xho I, after then pET-24a-gls recombinant plasmid is constructed through T4 ligase reaction. The recombinant plasmids are transformed into E. coli Rosetta-gami (DE3). The successfully validated positive clones are introduced into the fermentation medium.
When the OD600 of bacterial fluid reaches 0.6-0.8 in the fermentation under the condition of 37° C., 250 r/min, IPTG of a final concentration at 0.5 mmol/L is added into the fermentation broth, and transfer to conduct induction at 25° C. The content of GlcN and GlcNAc is determined after fermentation for 18 h. The result shows that the cumulative yield of GlcN and GlcNAc reaches 8.57 g/L, which is increased 2.4 times compared with the yield of single expression of gls (
The fed-batch fermentation is conducted in 7 L numerical control fermenter. The fermentation is conducted with an initial loading volume of 4 L, an inoculation amount of 5% vol at 37° C. firstly, and change to 25° C. after induction. Due to the acid generated in the fermentation process, ammonia is added to adjust pH in the experiment.
The above disclosure shows some specific embodiments of the present invention, however, the present invention is not limited to these embodiments. Various modifications of the disclosed embodiments as well as alternative embodiments of the invention will become apparent to persons skilled in the art. It is therefore contemplated that the appended claims will cover any such modifications or embodiments that fall within the scope of the invention.
| Number | Date | Country | Kind |
|---|---|---|---|
| 201710282955.4 | Apr 2017 | CN | national |
